{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-23-014227","form_type":"8-K","ticker":"CLNN","cik":"0001822791","company_name":"Clene Inc.","filed_at":"2023-05-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.883543+00:00","generated_at":"2026-06-15T02:43:57.215538+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Clene reports Q1 net loss of $11.8M, cash $18.4M; ALS data milestones expected mid-2023","bullets":["Net loss $11.8M ($0.15/sh) vs $13.4M ($0.21/sh) in Q1 2022; R&D $7.4M, G&A $3.4M.","Cash and marketable securities $18.4M as of Mar 31, expected to fund ops into Q3 2023.","ALS survival benefit data from HEALEY and RESCUE-ALS trials presented at AAN; biomarker/long-term survival data expected mid-2023.","Appointed Benjamin Greenberg, M.D., as Head of Medical; entered $25M equity facility with Lincoln Park.","MS regulatory discussions anticipated in Q4 2023; advancing partnership opportunities."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-23-014227","json":"https://secwatch.observer/filing/0001437749-23-014227.json","markdown":"https://secwatch.observer/filing/0001437749-23-014227.md","text":"https://secwatch.observer/filing/0001437749-23-014227.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1822791/000143774923014227/0001437749-23-014227-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1822791/000143774923014227/clnn20230505_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T02:43:57.215538+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"32a0728ec49cc039e7add0463d4364a72d5522b6","claim":"Clene Inc. reported first quarter ended March 31, 2023 results: net income $11.8 million, EPS $0.15 per share.","evidence_excerpt":"Clene reported a net loss of $11.8 million , or $0.15 per share, for the quarter ended March 31, 2023, compared to a net loss of $13.4 million , or $0.21 per share, for the same period in 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1822791/000143774923014227/0001437749-23-014227-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2023"},{"label":"Net income","value":"$11.8 million"},{"label":"EPS","value":"$0.15 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}